BMSCs may improve islet repairing by differentiating for new islets and change pancreatic microcirculation and be identified in a real-time manner using MRI in vivo
Kuanxiao Tang,Xiaoyan Xiao,Dayue Liu,Yunfeng Shen,Ying-ming Chen,YU WANG,Li Bao-ying,Yu Fei,MA DEDONG,Jin-hua Yan,Hua Liang,Daizhi Yang,Jianping Weng
2014-01-01
Abstract:Cellular replacement therapy for diabetes mellitus (DM) has received much attention. In this study, we investigated the effect of transplantation of autologous bone marrow-derived mesenchymal stem cells (ABMSCs) in streptozotocin (STZ)-induced diabetic miniature pigs. Miniature pig BMSCs were cultured, labeled with superparamagnetic iron oxide (SPIO) and transplanted into the pancreas of diabetic miniature pigs through targeted intervention. Blood glucose levels, intravenous and oral glucose tolerance test (OGTT), serum insulin, C-peptide and islets histology were analyzed. These transplanted cells were then identified by magnetic resonance imaging (MRI). The results showed that transplantation of ABMSCs reversed STZ-induced diabetes in miniature pigs. Blood glucose levels, intravenous, OGTT, serum insulin and C‐peptide were significantly recovered in the diabetic minipigs with the autologous BMSC (DMAB) transplantation group. In addition, the number of islets was significantly increased in this group compared to the diabetic minipig control (DMC) group with conventional therapy. These data suggested the implantation of autologous BMSCs for type 1 diabetes treatment can partially restore the function of islet β cells and maintain blood glucose homeostasis. Transplanted autologous BMSCs may improve islet repairing by differentiating for new islets and change pancreatic microcirculation and be identified in a real-time manner using MRI in vivo. Introduction Type 1 diabetes mellitus (T1D) is a chronic condition in which the pancreas produces little or no insulin due to autoimmune destruction of insulin-producing β cells in the islets. As diabetes is caused by the loss of a single cell type, cellular replacement therapy for diabetes mellitus (DM), especially T1D, has received much attention. More recently, additional efforts have been focused on the use of both autologous and allogeneic stem cells as sources of new islets (1-5). Bone marrow-derived mesenchymal stem cells (BMSCs) exhibit considerable developmental plasticity that can be induced to differentiate into insulin-producing cells in vitro. Although it is possible to induce β‐cell‐specific gene expression in murine and human BMSCs in vitro, insulin secretion of these differentiated cells is extremely low (2). Findings of previous studies have demonstrated that rodent BMSCs can adopt insulin-expressing phenotype (6), drive the phenotype of human BMSCs by the forced expression of β-cell transcription factors, and generate cells capable of glucose responsive insulin secretion (7). BMSCs transplanted into diabetic mice contribute to endocrine pancreatic regeneration (7-9). BMSCs reversed experimental diabetes in vivo by enhancing the regeneration and survival of endogenous β cells rather than repopulating the islets with transdifferentiated β cells (10,11). The potential mechanisms of these beneficial animal and clinical results from stem cell transplantation remain to be determined. However, the final destination of the cells and their fate following their transplantation in vivo has not been clearly determined. In this study, we used streptozotocin (STZ) to induce diabetes in miniature pigs, transplanted autologous BMSCs (ABMSCs) into the pancreas through targeted intervention, identified them in vivo by MRI scanning and monitored glycemic status and pancreatic islet β-cell function. Materials and methods Experimental animals. Tibetan miniature male pigs (3 months old) were purchased from the Guangdong Autografting of bone marrow mesenchymal stem cells alleviates streptozotocin‐induced diabetes in miniature pigs: Real‐time tracing with MRI in vivo KUANXIAO TANG1,2, XIAOYAN XIAO3, DAYUE LIU4, YUNFENG SHEN1, YINGMING CHEN4, YU WANG4, BAOYING LI2, FEI YU2, DEDONG MA2, JINHUA YAN1, HUA LIANG1, DAIZHI YANG1 and JIANPING WENG1 1Department of Endocrinology, The Third Affiliated Hospital of Sun Yat‐sen University, Guangzhou, Guangdong 510630; Departments of 2Geriatrics and 3Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong 250012; 4Department of Vascular Surgery and Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China Received January 19, 2014; Accepted March 31, 2014 DOI: 10.3892/ijmm.2014.1729 Correspondence to: Dr Jianping Weng, Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630,